重组人表皮生长因子联合前列地尔作用于糖尿病溃疡创面

背景：人内源性表皮生长因子的缺乏以及血流动力学的改变会导致创面不愈合的发生。目的：观察重组人表皮生长因子联合前列地尔作用于糖尿病溃疡动物模型创面的疗效。方法：Wistar大鼠40只建立糖尿病溃疡动物模型，随机等分为模型组、重组人表皮生长因子组、前列地尔组和重组人表皮生长因子+前列地尔组，分别予以1%碘伏清创、重组人表皮生长因子凝胶外敷、前列地尔静脉滴注、重组人表皮生长因子凝胶外敷和前列地尔静脉滴注联合治疗。结果与结论：干预后3，7，10，14 d观察发现，相比于模型组，重组人表皮生长因子和/或前列地尔治疗后，糖尿病皮肤溃疡大鼠溃疡面积减小、愈合时间缩短、创面动态愈合率上升(P < 0.01)，且两者联合治疗的效果优于重组人表皮生长因子和前列地尔单独治疗(P < 0.01)，而重组人表皮生长因子或前列地尔单独治疗的效果接近，提示重组人表皮生长因子与前列地尔联合使用比单纯使用前列地尔或单纯使用重组人表皮生长因子更能显著促进糖尿病溃疡创面的愈合。

Recombinant human epidermal growth factor combined with alprostadil for treatment of diabetic ulcers

BACKGROUND:Previous studies demonstrated that the lack of endogenous recombinant human epidermal growth factor (rhEGF) and the change of hemodynamic parameters will lead to nonunion.OBJECTIVE:To observe the effect of rhEGF combined with alprostadil on diabetic ulcers. METHODS:Forty Wistar rat models of diabetic ulcers were established and randomly divided into four groups: control (1% povidone iodine for debridement), rhEGF (rhEGF gel for spreading), alprostadil (intravenous administration of alprostadil) and rhEGF + alprostadil (rhEGF gel for spreading combined with intravenous administration of alprostadil). RESULTS AND CONCLUSION:At 3, 7, 10 and 14 days after intervention, the area of diabetic ulcers was diminished, healing time was shortened, and dynamic healing rate of wound surface was increased in the alprostadil , rhEGF and alprostadil + rhEGF groups (P < 0.01). The therapeutic effects were superior in the alprostadil + rhEGF group to those in the rhEGF group and alprostadil group (P < 0.01). The therapeutic effects were similar between rhEGF group and alprostadil group. These findings suggest that rhEGF combined with alprostadil better promotes the healing of diabetic ulcers than simple use of rhEGF or alprostadil.